{'fraction_non_alphanumeric': 0.02619515389652914, 'fraction_numerical': 0.003929273084479371, 'mean_word_length': 5.761061946902655, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 2, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Lessons learned from two survivors of greater than 90% Total Body Surface Area Full Thickness Burn Injuries using NovoSorb Biodegradable Temporizing Matrix™ and Autologous Skin Cell Suspension, RECELL™: A Case Series.

Since autologous split-thickness skin grafts (STSGs) are scarce and lab skin growth requires a significant amount of time, there are limited available treatment approaches for patients with full thickness >90% total burn surface area (TBSA). Additionally, to achieve the primary goal of skin coverage and resuscitation, there must exist a balance between fluid loss and metabolic derangement. Allografts and xenografts have traditionally been used early in the process to achieve these goals. Currently, novel approaches to treatment consider the additional use of synthetic dermal substitutes and autologous skin cell suspensions to improve outcomes. This case series describes the treatment course of patients with >90% TBSA full-thickness (FT) burn injuries using a staged, multifaceted approach of utilizing NovoSorb Biodegradable Temporizing Matrix™ (BTM) as the primary dermal substitute in conjunction with a RECELL™ Autologous Cell Suspensions Device applied with autograft and allograft to achieve improved resuscitation, limiting fluid loss, and finally skin coverage. Allograft and NovoSorb BTM™ was used early to cover excised burns, resulting in improved metabolic control by limiting the systemic inflammatory response syndrome (SIRS) and fluid loss. Both patients survived using this approach.